

Publishable Summary

This quarterly report provides an overview of the project progress within the AMYPAD Prognostic and Natural History Study (WP4), with a focus on the period from April to June 2021.

In Q2 2021, recruitment activity within the PNHS has been less affected by the ongoing COVID-19 crisis. Sites are having fewer local safety measures and the number of scan slots is increasing. Sites are still focused on reducing the backlog of scans instead of consenting new participants into AMYPAD PNHS, however, for some sites, the backlog seems to have been resolved. As a result, the recruitment numbers have slightly improved compared to Q1 2021 and the number of scans significantly increased compared to Q1 2021. Of note, we were able to maintain the double number of scans seen in March 2021 for the entire quarter.

In total, at the end of Q2 2021, AMYPAD PNHS had 1043 participants consented of which 909 have already received a PET scan. Moving forward, the Q3 of 2021 should see the approval of the global amendment v5.0 at UEDIN and v5.1 at Spain. At the beginning of Q3 2021, the number of consents and scans will decrease as most sites have their summer period in which fewer participants will consent into AMYPAD PNHS and fewer scans will be performed as sites are closed. In September 2021, sites should be able to resume recruitment activity at full speed after the summer period and the number of consents and scans should start to increase once more.

For more information: info@amypad.org

Acknowledgement: This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.



innovative
medicines
initiative